Member Info for Bagpuss67

Yes I got chased up proactively on a transaction by Market Surveillance - Takeover Panel who thought I had 3%...

312 richest person in Spain according to AI!

Thanks. Very helpful. It was just Bob talked at length in the March presentation about the outbreak in 2024 in South Devon and its in the news today and I wondered if they would have been a natural potential partner who might have been evaluating the tech.

Mycofiltration – trialling fungi-based filtration systems to remove pollutants from water

Not our tech?

Logo

Awards, Charity & Funding

South West Water to partner on seven new innovation projects to tackle pollution and improve river health

1 June, 2026

South West Water is partnering on seven new projects designed to help tackle some of the biggest environmental and operational challenges facing the water sector.

The projects have been awarded funding through the Ofwat Innovation Fund’s sixth Water Breakthrough Challenge.

Together, they will explore how new technologies, data and nature-based solutions can improve river health, reduce pollution, strengthen resilience and support a lower-carbon future.

Working with partners across the UK, South West Water will help develop and trial innovative approaches to improving water quality and resilience, from advanced data and monitoring tools to nature-based treatment solutions.

Carolyn Cadman, Chief Sustainability and Natural Resources Officer at South West Water, said:

“It is brilliant to be involved in such a wide range of innovation projects, especially those which are looking to nature and natural processes to solve our carbon and water management challenges.”

The projects include:

Open Catchment Intelligence, Insights and Integration (OCI³) – developing AI-powered tools to identify pollution risks and improve understanding of river catchments

Mycofiltration – trialling fungi-based filtration systems to remove pollutants from water

Smart Watch – using satellite technology to detect emerging risks to water quality

I’m a P-Leaver – exploring new ways to remove phosphorus and PFAS from wastewater and agricultural run-off

Smart Alarm Management – using AI to improve how operational alarms are managed during incidents

SI12 Challenge – investigating lower-carbon and less disruptive approaches to renewing water infrastructure

Splitting Biogas, Multiplying Value – exploring how wastewater biogas can be converted into hydrogen and graphene

Lauren Isbister, Mainstreaming Nature Based Solutions Project Manager at South West Water, is leading on three of the projects and said she’s excited to get started.

“We’re delighted that seven projects we are partnering on have been awarded funding. Innovation is essential to helping the water sector respond to some of the biggest environmental and operational challenges we face,” Lauren said.

“These projects bring together expertise from across industry, academia and environmental organisations to develop and test new approaches that could improve river health, strengthen resilience and support a more sustainable future for our region and the wider sector.”

The Ofwat Innovation Fund’s Water Breakthrough Challenge supports projects across England and Wales aimed at improving water quality, reducing pollution and accelerating innovation across the sector.

To be fair Bunsen. I'm being offered 1.12p for 1m

Contd

· Analytical validation

The FDA requested additional CARDIO inCode-Score test information relating to the lab processes used and the measures required to ensure samples are appropriately acquired and results are consistent and accurate when using the test. The Company is preparing this data in line with its FDA discussions and believes the provision of this information will satisfy the FDA requirements.

· Cybersecurity:

This is an area where the Company does not see a major impediment and it will provide Quality Assurance documentation to show its systems meet cybersecurity standards with these standards forming part of the Company's Quality Management System.

The Company is working closely with the FDA to confirm that the above deficiencies are satisfactorily resolved by the provision of the above data and information. This is expected to be submitted at the end of Q1 2026 which would allow for an expected response around the end of Q2 2026. FDA may not give this confirmation given its nature as a regulator who reserves their right to ask additional questions, but the Board feels confident that this should be the case.

It was June. If the studies were on time. Not sure they were quite as trivial as you say..

Clinical validation - Ancestry/Ethical make-up of the original Northern California cohort

The FDA has requested further data on sub-group analysis of the African American population as the Kaiser Permanente Northern California (KPNC) cohort was not felt to be sufficiently powered for a relevant cross-section of the African American population. The African American population is generally not well represented in US healthcare plans due to socio-economic issues and there was a reduced number (2,084 patients) of African American ancestry in the California dataset of 63,000 patients.

Fortunately, the KPNC data set is a subset of a much larger Kaiser Permanente data set of c400,000 patient records (the KPRB dataset) capturing patient information from other US states where there is a greater representative population of African American patients (estimated at >10,000). This data set has been constructed on a similar basis to the KPNC cohort i.e. with the relevant genetic information to be able to demonstrate the genetic risk and incidence of CHD.

The Company has informed the FDA of the KPRB data set and is working with the FDA to ensure that data provided from the new data set will satisfy the FDA requirements. The Company will provide the analysis of this data as an update to its De Novo submission to resolve this outstanding deficiency. The new data set will also provide a more robust population data set.

Preparation for the study has started and is expected to take approximately 3 months to complete. The Company expects to provide more substantive data across all its population sub-groups, but especially the African American population.

· Clinical validation - Medical Chart review of the records provided by Kaiser Permanente to confirm their accuracy of coronary event (case and non-case) classification

Kaiser Permanente is a well-respected US healthcare institution and leader in US healthcare standards of care, especially in Cardiology. It uses the internationally recognised ICD codes for clinically recording CHD events e.g. heart attack. These events appear on medical records if the patient has had a coronary event. The ICD codes are widely used by US physicians and the FDA has requested a test sample of the 'cases' and 'non-cases' to be reviewed by Kaiser Permanente cardiologists to ensure they are correct.

The Company believes there is a very low possibility that there are errors in the Kaiser Permanente medical record event code classifications and has agreed with Kaiser to take 500 blinded medical record ICD code 'cases' and 'non-cases' and have two independent Kaiser cardiologists review the underlying medical notes to assess whether a cardiovascular event was correctly classified. the Directors expect that this can be completed over a few days once the above study is complete.

· Analytical

Personally I think its material. Look at it the other way. If they haven't' submitted the studies and there is a significant delay caused to possible FDA approval that would be material news. Maybe though we will have to wait for the results for that update . We shall see soon enough as I guess the results are due soon.

They haven't announced that the additional materials/ studies requested have been completed an submitted. They originally thought it would be 3 months from that point to approval by the FDA

Morning all. That's a fantastic rns so Ie increased my holding despite the muted marhet reaction. There has been some great analysis of the potential sum of the parts valuation. I'm my opinion this rns starts to add weight to those numbers. When the first PE round occurs on this spin out I expect this overall group valuation to have been left some way behind us.

PS I'm not a deramper. I hold 1.5% and took part in the placing... Just understood the FDA date to be June and also personally expected the completion of the study needed by the FDA would be rns'd. I also expect a very significant share price uplift when the FDA is granted.

As at 21 Jan

Preparation for the study has started and is expected to take approximately 3 months to complete. The Company expects to provide more substantive data across all its population sub-groups, but especially the African American population.

Wasn't it 3 months to get the additional data collected and filed ie end of Q1 (now late) and hopefully approval in June (according to info at the time of the raise)...

So I think we are waiting for news that the additional FDA materials have been submitted and then it may be a further 3 months to get approval unless expedited in some way..

Hi. Apologies. Maven did get appear to get some in the raise but let themselves be diluted and Octopus didn't appear to increase and hence were diluted. Couldn't see a TR1 from Dowgate but guess they got diluted below 3%. Don't see First Equity/ Armstrong or Santi as a funds. The Chesterfields look like an interesting family but I couldn't at first glance find out much about them (apart from some interesting names of family members!)...

Laura. Where do you get that 3 funds have increased from. Looks like the main ones allowed themselves to be diluted in the raise (as they are not permitted to follow on) and the one trimmed a bit after that. Thanks

They need to submit the results of the further trials to the FDA before any approval is possible. That was supposed to be at the end of March so that approval could have possibly been in June. Heading for a 2 month delay unless they pull their fingers out

Maybe they saw APTAs super greedy package and thought why not....

This was supposed to be submitted by the end of Q1 to hopefully enabler approval in H1. They appear to be well behind and needed to get that sorted before considering how they could boost their reward. IMHO

That was me..looking forward to this getting into the 20s...